| Placebo | Maraviroc 300 mg BID | Pvalue |
---|---|---|---|
ACR components | Â | Â | Â |
   Tender/painful joint count | -3.41 (1.19) [n = 33] | -4.89 (0.84) [n = 77] | 0.294 |
   Swollen joint count | -3.43 (0.95) [n = 33] | -3.48 (0.66) [n = 77] | 0.966 |
   Patient's assessment of arthritis pain | -6.09 (4.06) [n = 33] | -8.30 (2.85) [n = 77] | 0.644 |
   Patient's global assessment of arthritis | -6.78 (4.06) [n = 33] | -8.55 (2.88) [n = 76] | 0.712 |
   Physician's global assessment of arthritis | -0.36 (0.15) [n = 32] | -0.49 (0.11) [n = 75] | 0.490 |
   HAQ-DI | -0.06 (0.13) [n = 20] | -0.18 (0.08) [n = 55] | 0.396 |
SF-36 version 2 (acute) | Â | Â | Â |
   Physical component summary | 4.81 (1.65) [n = 19] | 3.14 (1.04) [n = 53] | 0.344 |
   Mental component summary | 0.61 (2.25) [n = 19] | 1.17 (1.41) [n = 53] | 0.818 |